EUVIMEDEUVIMED entdecken
Crossref

A Potential 3‐in‐1 Combined AntiSARS‐CoV‐2 Therapy Using Pulmonary MIL‐100(Fe) Formulation

Beatrice Fodor iD, Inés Álvarez-Miguel iD, Catalina Biglione iD, Guillermo G López iD, África González-Fernández iD, Fabrice Salles iD, Tania Hidalgo iD, Patricia Horcajada iD

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202403988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Beatrice Fodor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Porous Materials Unit, IMDEA Energy, Ramón de la Sagra 3, Móstoles-Madrid, 28935, Spain. Hauptthemen laut MEDLINE: Metal-Organic Frameworks, Antiviral Agents, COVID-19 Drug Treatment, SARS-CoV-2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: HORIZON EUROPE Marie Sklodowska-Curie Actions (HORIZON-MSCA-2021-PF-01), Comunidad de Madrid, H2020 Marie Skłodowska-Curie Actions (H2020-MSCA-IF-2019).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence and rapid propagation of infectious diseases, including the COVID‐19 pandemic, has evidenced the vulnerabilities in global health surveillance, the ease of transmission, and the imperative need for effective treatments. In this context, nanomedicines based on metal–organic frameworks (MOFs) have garnered great relevance as promising drug delivery platforms in a large range of complex diseases (e.g., cancer, and infections). However, most research has focused on sensing with scarce examples in antiviral therapies. Hence, here a pioneer combined 3‐in‐1 effect anti‐COVID pulmonary multitherapy based on the mesoporous iron(III) carboxylate MIL‐100(Fe) nanoparticles is proposed, with the proven intrinsic MOF effect, associated with favipiravir drug into their porosity and heparin on their external surface. A significant antiviral effect against a real scenario of COVID‐19 infection is demonstrated (≈70% inhibition), ensuring a suitable cellular viability. Further, a convenient pulmonary formulation is prepared based on mannitol‐based microspheres, testing its safety and biodistribution in healthy mice. No significant side effects are observed, reaching successfully the deep lungs, emphasizing a reduced immunological response compared to their controls. Therefore, these promising results open new horizons for future (pre)clinical trials targeting challenging infectious/pulmonary pathologies, enhancing the feasibility of designing customized therapeutic MOF platforms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metal-Organic FrameworksAntiviral AgentsCOVID-19 Drug TreatmentSARS-CoV-2PyrazinesAnimalsMiceHumansCOVID-19AmidesLungTissue DistributionNanoparticlesVero Cells

Stichwörter der Autor:innen

COVID‐19heparinin vivolungsmetal–organic frameworksmultitherapynanomedicines

Substanzen

Metal-Organic FrameworksAntiviral AgentsfavipiravirAmidesPyrazines

Autor:innen und Institutionen

  • Advanced Porous Materials Unit, IMDEA Energy, Ramón de la Sagra 3, Móstoles-Madrid, 28935, Spain.
  • Universidad Autónoma de Madrid, Madrid, 28049, Spain.
  • CINBIO, Immunology Group, Universidade de Vigo, Vigo, 36310, Spain.
  • Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Pontevedra, 36312, Spain.
  • ICGM, Université Montpellier, CNRS ENSCM, Montpellier, 34090, France.

ORCID-Profile: Beatrice Fodor, Inés Álvarez-Miguel, Catalina Biglione, Guillermo G López, África González-Fernández, Fabrice Salles, Tania Hidalgo, Patricia Horcajada

Förderung

  • HORIZON EUROPE Marie Sklodowska-Curie Actions (HORIZON-MSCA-2021-PF-01)
  • Comunidad de Madrid
  • H2020 Marie Skłodowska-Curie Actions (H2020-MSCA-IF-2019)

Zitieren

APA

Fodor, B., Álvarez-Miguel, I., Biglione, C., López, G. G., González-Fernández, Á., Salles, F., Hidalgo, T., & Horcajada, P. (2025). A Potential 3‐in‐1 Combined AntiSARS‐CoV‐2 Therapy Using Pulmonary MIL‐100(Fe) Formulation. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202403988

Vancouver

Fodor B, Álvarez-Miguel I, Biglione C, López GG, González-Fernández Á, Salles F, et al. A Potential 3‐in‐1 Combined AntiSARS‐CoV‐2 Therapy Using Pulmonary MIL‐100(Fe) Formulation. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202403988

BibTeX
@article{Fodor2025,
  author = {Fodor, Beatrice and Álvarez-Miguel, Inés and Biglione, Catalina and López, Guillermo G and González-Fernández, África and Salles, Fabrice and Hidalgo, Tania and Horcajada, Patricia},
  title = {A Potential 3‐in‐1 Combined AntiSARS‐CoV‐2 Therapy Using Pulmonary MIL‐100(Fe) Formulation},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202403988}
}
Kostenlos starten →